Proove Biosciences Offering Test to Assisting in Treating Jaw Disorder Known as TMD

Proove Biosciences Offering Test to Assisting in Treating Jaw Disorder Known as TMD

Proove Biosciences recently announced the launch of a test that may help doctors treat patients with temporomandibular joint disorder (TMD), a painful condition that can be associated with fibromyalgia. The product is called the Proove TMD Profile test.

TMD is characterized by a dysfunction in the muscles that move the jaw, and patients with TMD experience pain and restricted jaw movement.  Although its causes are unknown, TMD has been seen to occur simultaneously with other painful conditions, such as fibromyalgia and chronic fatigue syndrome.

“With such an abundance of Americans suffering from the painful symptoms of TMD, dentists, pain physicians and oral surgeons are lacking ways of diagnosing and treating suffering patients,” said Brian Meshkin, Proove Biosciences’ founder and CEO, in a news release. “Building off of the incredible work done by patient advocates, academic researchers, and the largest NIH-funded prospective study in chronic pain, we are honored to partner with these experts to launch Proove TMD Profile, which will undoubtedly aid patients and clinicians by analyzing DNA markers and recommending the most appropriate treatment based on scientific evidence.”

Proove TMD Profile works by analyzing genetic variants in the adrenergic and serotonergic pathways, as well as patient self-reported stress and tender points. In this way, it can help doctors evaluate pain perception and understand the mechanisms involved in the onset of TMD pain, which can help them in developing more personalized treatments.

The profile, according the company’s website, also offers pharmacological insights, based on its results, into how each patient is likely to respond to drug therapy prior to treatment and a genetic potential predisposition to addiction. This could be of importance, because a recent study showed that dentists frequently prescribe opioid painkillers to TMD patients ages 14 to 17, as well as young adults ages 18 to 24.

The National Institute of Dental and Craniofacial Research estimates that 10 million Americans are affected by TMD.